Agenus Inc
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a sap… Read more
Agenus Inc (AGEN) - Net Assets
Latest net assets as of September 2025: $-280.87 Million USD
Based on the latest financial reports, Agenus Inc (AGEN) has net assets worth $-280.87 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($233.89 Million) and total liabilities ($514.76 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-280.87 Million |
| % of Total Assets | -120.08% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -533.24% |
| Growth Volatility | 123.93 |
Agenus Inc - Net Assets Trend (1999–2024)
This chart illustrates how Agenus Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Agenus Inc (1999–2024)
The table below shows the annual net assets of Agenus Inc from 1999 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-306.42 Million | -106.51% |
| 2023-12-31 | $-148.38 Million | -170.27% |
| 2022-12-31 | $-54.90 Million | -214.60% |
| 2021-12-31 | $47.91 Million | +122.65% |
| 2020-12-31 | $-211.50 Million | +8.58% |
| 2019-12-31 | $-231.34 Million | -32.54% |
| 2018-12-31 | $-174.55 Million | -130.22% |
| 2017-12-31 | $-75.82 Million | -93.77% |
| 2016-12-31 | $-39.13 Million | -155.32% |
| 2015-12-31 | $70.73 Million | +207.27% |
| 2014-12-31 | $23.02 Million | +613.68% |
| 2013-12-31 | $-4.48 Million | +62.72% |
| 2012-12-31 | $-12.02 Million | +42.30% |
| 2011-12-31 | $-20.83 Million | -41.64% |
| 2010-12-31 | $-14.71 Million | +13.36% |
| 2009-12-31 | $-16.98 Million | +29.03% |
| 2008-12-31 | $-23.92 Million | +49.18% |
| 2007-12-31 | $-47.06 Million | -170.56% |
| 2006-12-31 | $-17.39 Million | -154.53% |
| 2005-12-31 | $31.90 Million | -70.03% |
| 2004-12-31 | $106.44 Million | +1.14% |
| 2003-12-31 | $105.25 Million | +35.35% |
| 2002-12-31 | $77.76 Million | +2.41% |
| 2001-12-31 | $75.92 Million | -34.94% |
| 2000-12-31 | $116.70 Million | +125.73% |
| 1999-12-31 | $51.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Agenus Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 214528000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $236.00K | % |
| Other Comprehensive Income | $-1.40 Million | % |
| Other Components | $1.86 Billion | % |
| Total Equity | $-326.38 Million | 100.00% |
Agenus Inc Competitors by Market Cap
The table below lists competitors of Agenus Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kongsberg Automotive ASA
PINK:KGAUF
|
$112.04 Million |
|
Greenfire Resources Ltd.
NYSE:GFR
|
$112.05 Million |
|
HeidelbergCement India Limited
NSE:HEIDELBERG
|
$112.07 Million |
|
ARMATA PHARMACEUT.
F:TG1N
|
$112.09 Million |
|
First Mining Gold Corp
OTCQX:FFMGF
|
$111.98 Million |
|
Logwin AG
XETRA:TGHN
|
$111.95 Million |
|
Community Bank of the Bay
PINK:CBOBA
|
$111.94 Million |
|
Mycenax Biotech
TWO:4726
|
$111.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Agenus Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -160,331,000 to -326,380,000, a change of -166,049,000.
- Net loss of 227,212,000 reduced equity.
- New share issuances of 38,823,000 increased equity.
- Other comprehensive income decreased equity by 443,000.
- Other factors increased equity by 22,783,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-227.21 Million | -69.62% |
| Share Issuances | $38.82 Million | +11.9% |
| Other Comprehensive Income | $-443.00K | -0.14% |
| Other Changes | $22.78 Million | +6.98% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Agenus Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $341.93 | $3.99 | x |
| 2000-12-31 | $567.93 | $3.99 | x |
| 2001-12-31 | $323.74 | $3.99 | x |
| 2002-12-31 | $283.57 | $3.99 | x |
| 2003-12-31 | $323.92 | $3.99 | x |
| 2004-12-31 | $285.85 | $3.99 | x |
| 2005-12-31 | $83.99 | $3.99 | x |
| 2006-12-31 | $-45.56 | $3.99 | x |
| 2007-12-31 | $-121.42 | $3.99 | x |
| 2008-12-31 | $-45.38 | $3.99 | x |
| 2009-12-31 | $-25.78 | $3.99 | x |
| 2010-12-31 | $-18.26 | $3.99 | x |
| 2011-12-31 | $-26.55 | $3.99 | x |
| 2012-12-31 | $-14.90 | $3.99 | x |
| 2013-12-31 | $-3.01 | $3.99 | x |
| 2014-12-31 | $7.70 | $3.99 | x |
| 2015-12-31 | $18.09 | $3.99 | x |
| 2016-12-31 | $-8.99 | $3.99 | x |
| 2017-12-31 | $-15.41 | $3.99 | x |
| 2018-12-31 | $-31.14 | $3.99 | x |
| 2019-12-31 | $-33.39 | $3.99 | x |
| 2020-12-31 | $-23.61 | $3.99 | x |
| 2021-12-31 | $3.01 | $3.99 | x |
| 2022-12-31 | $-4.35 | $3.99 | x |
| 2023-12-31 | $-8.96 | $3.99 | x |
| 2024-12-31 | $-15.20 | $3.99 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Agenus Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -219.61%
- • Asset Turnover: 0.46x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-37.30%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | -35.01% | -18100.00% | 0.00x | 1.08x | $-23.27 Million |
| 2000 | -40.04% | -10557.24% | 0.00x | 1.10x | $-58.40 Million |
| 2001 | -96.86% | -1614.51% | 0.05x | 1.23x | $-81.13 Million |
| 2002 | -71.86% | -1637.92% | 0.04x | 1.15x | $-63.65 Million |
| 2003 | -62.65% | -1481.76% | 0.03x | 1.33x | $-76.46 Million |
| 2004 | -52.76% | -7942.85% | 0.01x | 1.25x | $-66.81 Million |
| 2005 | -232.31% | -11762.88% | 0.01x | 3.27x | $-77.29 Million |
| 2006 | 0.00% | -7495.73% | 0.01x | 0.00x | $-50.14 Million |
| 2007 | 0.00% | -662.70% | 0.12x | 0.00x | $-32.09 Million |
| 2008 | 0.00% | -1082.49% | 0.05x | 0.00x | $-26.31 Million |
| 2009 | 0.00% | -909.36% | 0.07x | 0.00x | $-28.62 Million |
| 2010 | 0.00% | -652.05% | 0.11x | 0.00x | $-20.44 Million |
| 2011 | 0.00% | -844.63% | 0.14x | 0.00x | $-20.64 Million |
| 2012 | 0.00% | -70.95% | 0.46x | 0.00x | $-9.56 Million |
| 2013 | 0.00% | -987.62% | 0.09x | 0.00x | $-29.62 Million |
| 2014 | -184.58% | -608.94% | 0.09x | 3.24x | $-44.79 Million |
| 2015 | -124.25% | -354.12% | 0.10x | 3.42x | $-94.95 Million |
| 2016 | 0.00% | -562.60% | 0.14x | 0.00x | $-123.08 Million |
| 2017 | 0.00% | -281.48% | 0.31x | 0.00x | $-113.11 Million |
| 2018 | 0.00% | -434.14% | 0.27x | 0.00x | $-142.45 Million |
| 2019 | 0.00% | -71.75% | 0.97x | 0.00x | $-85.12 Million |
| 2020 | 0.00% | -205.19% | 0.41x | 0.00x | $-160.55 Million |
| 2021 | -69.47% | -8.09% | 0.63x | 13.53x | $-27.37 Million |
| 2022 | 0.00% | -224.51% | 0.24x | 0.00x | $-213.95 Million |
| 2023 | 0.00% | -157.22% | 0.50x | 0.00x | $-229.73 Million |
| 2024 | 0.00% | -219.61% | 0.46x | 0.00x | $-194.57 Million |
Industry Comparison
This section compares Agenus Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Agenus Inc (AGEN) | $-280.87 Million | -35.01% | N/A | $112.04 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |